

Advancement of the pharmaceutical technologies' unit

Reig Jofre launches a new hospital medicine in Spain and Europe for the treatment of narcolepsy



- Reig Jofre expands its portfolio of hospital medicines with the launch of Sodium Oxybate 500 mg/ml oral solution EFG indicated in the treatment of narcolepsy with cataplexy in adult patients
- Reig Jofre will market this medicine in Spain and Europe through its commercial network in the markets where it has direct sales and through its network of business partners in the rest of the countries

Barcelona (Spain), March 10, 2020, Reig Jofre, a pharmaceutical company listed on the Spanish continuous market, has recently launched **Sodium Oxybate 500 mg/ml oral solution EFG**, oral solution for hospital use developed by the R&D team from Barcelona plant, indicated in the treatment of narcolepsy with cataplexy in adult patients.

Reig Jofre begins marketing this hospital medicine through its own sales teams in Spain, the United Kingdom, Sweden, Denmark, Finland and France, markets in which it expects to reach a significant position. The company will also market this medicine in the rest of the European markets thanks to its extensive network of business partners.

The specialization in pharmaceutical products for hospital use belonging to the area of pharmaceutical technologies, mostly developed by the R&D teams of the Barcelona plant, together with penicillin-derived antibiotics produced in Toledo plants, has been the spearhead of the internationalization of the listed Reig Jofre.



Reig Jofre closed 2019 with a turnover of 200 million euros, of which European markets accounted for 45% of sales. Spain contributed 45%, the rest of the world 10%. For the marketing of its developments, Reig Jofre has its own sales network in 7 countries in Europe and Southeast Asia and trade relations with more than 130 partners (distributors and licensees) in 72 countries on five continents.

Receive updated news about Reig Jofre by registering with the company's **subscription centre** via our corporate website: **www.reigjofre.com**

About Reig Jofre

Founded in 1929 in Barcelona, Reig Jofre is a family-controlled pharmaceutical company listed on the Spanish Stock Exchange's continuous market and dedicated to the research, development, manufacture and marketing of pharmaceutical products and nutritional supplements from its four plants in Toledo (2), Barcelona and Malmö (Sweden). Reig Jofre structures its product development activity in three business areas: (1) *Pharmaceutical technologies* specialized in sterile and lyophilized injectables, and antibiotics derived from penicillin; (2) *Specialty pharmacare* in Skin, Hair and Nail Health; Health and Joint Pain and Women's Health (developed and produced internally), and (3) *Consumer Healthcare* with products aimed at the consumer under the Forté Pharma brand, mainly in France, Belgium, Spain and Portugal, and other OTCs. Reig Jofre has more than 1000 employees, direct sales in 7 countries and more than 130 business partners in 72 countries around the world. The company closed 2019 with a turnover of 200 million Euros. Reig Jofre is listed the ticker RJF. Share capital: 76,062,457 shares

Further information

Inma Santa-Pau - Director of Communication and Investor Relations
Tel. (+34) 935 450 078 - inma.santapau@reigjofre.com
www.reigjofre.com